Intravenously injecting CPG2 or a CPG2 conjugate leads to a low amount of CPG2 in cancer tissues, although the expected goal of using a CPG2 conjugate is to realize an intratumoral enrichment of CPG2. Here, SYNE1 is linked to cancer.